Section Arrow
VRDN.NASDAQ
- Viridian Therapeutics
Quotes are at least 15-min delayed:2026/01/07 17:05 EST
After Hours
Last
 31.03
+0.46 (+1.50%)
Bid
28.97
Ask
32.55
High 31.03 
Low 30.57 
Volume 72.02K 
Regular Hours (Closed)
Last
 30.57
-0.15 (-0.49%)
Day High 
31.47 
Prev. Close
30.72 
1-M High
34.04 
Volume 
1.82M 
Bid
28.97
Ask
32.55
Day Low
29.895 
Open
31.47 
1-M Low
28.96 
Market Cap 
2.93B 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 31.4 
20-SMA 31.84 
50-SMA 29.46 
52-W High 34.04 
52-W Low 9.9 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-3.03/-2.12
Enterprise Value
2.95B
Balance Sheet
Book Value Per Share
3.29
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
302.00K
Operating Revenue Per Share
0.02
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
ASBPAspire Biopharma Holdings Inc.0.1256+0.0206+19.62%-- 
After Hours 0.128 +0.0024 +1.91%
ERASErasca5.17+1.54+42.42%-- 
After Hours 4.56 -0.61 -11.80%
RXRXRecursion Pharmaceuticals4.86+0.31+6.81%-- 
After Hours 4.81 -0.05 -1.03%
VTYXVentyx Biosciences13.73+3.68+36.62%-- 
After Hours 13.73 0 0.00%
GLUEMonte Rosa Therapeutics23.28+7.27+45.41%54.09PE
After Hours 23.65 +0.37 +1.59%
Industry overview quotes are at least 15 minutes delayed
Business Description
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly knownas VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED).
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.